Evaluation study on dementia Berlin-Brandenburg (VDBB)Epidemiological investigation on the impact of diagnosis, based on biomarker criteria, onto the treatment strategy on patients with cognitive impairment, in the sense of knowledge generating medicine. - VDBB-02

DTZ Berlin0 个研究点目标入组 41 人开始时间: 2017年5月30日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Adults age = 75
•2.Patients with mild cognitive impairment (MCI) or mild dementia (MMST = 20 points or DemTect = 9 points) with suspicion of Alzheimer's (Hachinski test < 4 points)
•3.According to guidelines with biomarkers continuative diagnostics is recommended by the examining physician.
•4.The patient is voluntarily taking part in the study and has given his written permission for the use of his pseudonymized patient data.

•1. Previous amyloid PET scan with available investigating results.
•2. Simultaneous participating in a clinical trial on disease-modifying treatments for Alzheimer's
•3.Severe depression (GDS > 10 points)
•4.The occurrence of a neurological disorder, frequently associated with dementia, e.g. Parkinson's disease
•5.Significant discrepancies in the results of physical examination, vital functions and laboratory examination, which require further examination or treatment
•6.Dependency disorders (e.g. benzodiazepine, alcohol)
•7.Intake of cognitive impairing medication
•8.Serious illness, that could prevent a participation throughout the entire observation period
•9. Lives at a nursing home.
•10. Pregnancy

发起方

DTZ Berlin